| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.096 | 0.08 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.084 | 0.08 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.08 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.055 | 0.08 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |